These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 1980930

  • 41. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
    González Maqueda I.
    Coron Artery Dis; 1994 Nov; 5(11):909-18. PubMed ID: 7719523
    [Abstract] [Full Text] [Related]

  • 42. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
    Searle M, Dathan R, Dean S, Christensen CC, Westheim A.
    Eur J Clin Pharmacol; 1990 Nov; 39(3):299-300. PubMed ID: 2147909
    [Abstract] [Full Text] [Related]

  • 43. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
    Talseth T, Westlie L, Daae L.
    Am Heart J; 1991 Jan; 121(1 Pt 2):280-5. PubMed ID: 1824651
    [Abstract] [Full Text] [Related]

  • 44. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D, Madsbu HP.
    Am J Cardiol; 1987 May 29; 59(14):68G-72G. PubMed ID: 2884855
    [Abstract] [Full Text] [Related]

  • 45. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
    Frick MH, Halttunen P, Himanen P, Huttunen M, Pörsti P, Pitkäjärvi T, Pöyhönen L, Pyykönen ML, Reinikainen P, Salmela P.
    Br J Clin Pharmacol; 1986 May 29; 21 Suppl 1(Suppl 1):55S-62S. PubMed ID: 2939868
    [Abstract] [Full Text] [Related]

  • 46. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL.
    Am J Cardiol; 1987 May 29; 59(14):46G-50G. PubMed ID: 2884853
    [Abstract] [Full Text] [Related]

  • 47. Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
    Lijnen P, Fagard R, Staessen J, Lissens W, Amery A.
    J Cardiovasc Pharmacol; 1989 Aug 29; 14(2):319-25. PubMed ID: 2476608
    [Abstract] [Full Text] [Related]

  • 48. Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
    Giordano M, Castellino P, Solini A, Canessa ML, DeFronzo RA.
    Metabolism; 1997 Nov 29; 46(11):1316-23. PubMed ID: 9361692
    [Abstract] [Full Text] [Related]

  • 49. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
    Jansson JH, Johansson B, Boman K, Nilsson TK.
    Eur J Clin Pharmacol; 1991 Nov 29; 40(4):321-6. PubMed ID: 1828764
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
    Bönner G, Schmieder R, Chrosch R, Weidinger G.
    Cardiovasc Drugs Ther; 1997 Mar 29; 11(1):21-6. PubMed ID: 9140673
    [Abstract] [Full Text] [Related]

  • 52. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
    Baez MA, Garg DC, Jallad NS, Weidler DJ.
    Br J Clin Pharmacol; 1986 Mar 29; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
    [Abstract] [Full Text] [Related]

  • 53. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
    Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D.
    Am J Cardiol; 1993 Mar 01; 71(7):575-81. PubMed ID: 8438744
    [Abstract] [Full Text] [Related]

  • 54. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.
    Hobbs FR, Khan T, Collins B.
    Br J Gen Pract; 2005 Jun 01; 55(515):437-43. PubMed ID: 15970067
    [Abstract] [Full Text] [Related]

  • 55. [Effects of ketanserin on glucose metabolism in hypertensive diabetic subjects].
    Carleo R, Gobbo M, Bonavita M, De Matteo A, Gallo M, Gatti A.
    Boll Soc Ital Biol Sper; 1990 Jul 01; 66(7):639-46. PubMed ID: 1964564
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J.
    Am Heart J; 1988 Dec 01; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [Abstract] [Full Text] [Related]

  • 58. Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function.
    Gillin AG, Fletcher PJ, Horvath JS, Hutton BF, Bautovich GJ, Tiller DJ.
    Am J Cardiol; 1989 Apr 15; 63(13):950-4. PubMed ID: 2522729
    [Abstract] [Full Text] [Related]

  • 59. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R, D'Angelo A, Pati T, Al Awady M, Tronca R, Crepaldi G.
    Am Heart J; 1988 Dec 15; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [Abstract] [Full Text] [Related]

  • 60. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers.
    Englert RG, Barlage U.
    Am Heart J; 1991 Jan 15; 121(1 Pt 2):311-6. PubMed ID: 1670745
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.